drugset / Trial / NCT00109408

A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis

NCT00109408 ↗

Phase 3 Completed 673 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus methotrexate in patients with active rheumatoid arthritis (RA). Patients will be randomized to receive tocilizumab 8mg/kg iv every 4 weeks plus placebo po weekly, or methotrexate 7.5-20mg po weekly plus placebo iv every 4 weeks. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Timeline

Start
2005-07
Primary completion
2007-12
Completion
2007-12

Outcome

Met primary endpoint

paper the intention-to-treat analysis demonstrated that tocilizumab was better than methotrexate treatment with a higher ACR20 response (69.9 vs 52.5%; p<0.001) PMID 19297346 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule 20 mg Oral
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous

Indications